Valemetostat + Atezolizumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jan 29, 2025 → Jan 1, 2027
NCT ID
NCT06807632About Valemetostat + Atezolizumab
Valemetostat + Atezolizumab is a phase 1 stage product being developed by Daiichi Sankyo for Extensive-stage Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06807632. Target conditions include Extensive-stage Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06807632 | Phase 1 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer